Applications and Challenges of Artificial Intelligence and Big Data in Drug Regulation
Therapeutic Innovation & Regulatory Science · 2026-05 · 60 (3) · 748-755
DOI: 10.1007/s43441-026-00946-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 05.03.2026. Verfasst von Zhao Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Executive Development, National Medical Products Administration, Beijing, 100073, China. Hauptthemen laut MEDLINE: Artificial Intelligence, Big Data, Drug and Narcotic Control. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
Artificial intelligence (AI) and big data are increasingly applied in drug regulation and have demonstrated significant potential worldwide. The U.S. Food and Drug Administration (FDA) has developed a relatively comprehensive approach through strategic frameworks, regulatory guidelines, and pilot programs. The European Medicines Agency (EMA) has promoted AI adoption via the Big Data Task Force, DARWIN EU®, and a multi-annual work plan, while Japan, Canada, and other countries have also advanced relevant initiatives and strengthened international cooperation. In China, smart regulation has been incorporated into the "14th Five-Year Plan" and subsequent strategies, with progress in establishing national regulatory data platforms, pharmaceutical traceability systems, and pilot AI applications. Nevertheless, AI in drug regulation remains at an exploratory stage, facing challenges such as limited model reliability and interpretability, insufficient data standards and interoperability, regulatory gaps, and ethical as well as public trust concerns. Future progress will depend on strengthening regulatory standards, enhancing data governance, improving regulatory capacity, and deepening international collaboration to achieve more scientific, intelligent, and efficient drug regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Executive Development, National Medical Products Administration, Beijing, 100073, China.
- Institute of Executive Development, National Medical Products Administration, Beijing, 100073, China. 13661318348@163.com.
- China Society for Drug Regulation, Beijing, 100050, China. ylyl1220@163.com.
Zitieren
APA
Liu, Z., Zheng, Y., Fang, J., & Yuan, L. (2026). Applications and Challenges of Artificial Intelligence and Big Data in Drug Regulation. Therapeutic Innovation & Regulatory Science, 60(3), 748-755. https://doi.org/10.1007/s43441-026-00946-8
Vancouver
Liu Z, Zheng Y, Fang J, Yuan L. Applications and Challenges of Artificial Intelligence and Big Data in Drug Regulation. Therapeutic Innovation & Regulatory Science. 2026;60(3):748-755. doi:10.1007/s43441-026-00946-8
BibTeX
@article{Liu2026,
author = {Liu, Zhao and Zheng, Yang and Fang, Jun and Yuan, Lin},
title = {Applications and Challenges of Artificial Intelligence and Big Data in Drug Regulation},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2026},
volume = {60},
number = {3},
pages = {748--755},
doi = {10.1007/s43441-026-00946-8}
}
EUVIMED